Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107M
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
1.73M
-
Shares change
-
-128K
-
Total reported value, excl. options
-
$9.55M
-
Value change
-
-$1.35M
-
Put/Call ratio
-
0.3
-
Number of buys
-
9
-
Number of sells
-
-15
-
Price
-
$5.53
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q4 2021
35 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.73M shares
of 107M outstanding shares and own 1.62% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (655K shares), BlackRock Inc. (255K shares), GEODE CAPITAL MANAGEMENT, LLC (134K shares), MORGAN STANLEY (124K shares), Equitable Holdings, Inc. (102K shares), AMERIPRISE FINANCIAL INC (94.5K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (93.5K shares), CITADEL ADVISORS LLC (40.8K shares), STATE STREET CORP (37.5K shares), and BANK OF AMERICA CORP /DE/ (31.8K shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.